Topic:

Emerging Markets

Latest Headlines

Latest Headlines

GSK's ViiV turns to Chinese company for cheap supply of Tivicay API

The HIV-oriented joint venture of Pfizer, GlaxoSmithKline and Japan's Shionogi is turning to a Chinese manufacturer for a cheap supply of dolutegravir, the active ingredient in its Tivicay. The deal is seen as a way to cut the cost in China and some other developing countries of the JV's newest HIV fighter.

J&J's Ethicon sponsors 20+ clinical trials to advance bariatric surgery globally

Ethicon, the Johnson & Johnson unit devoted to surgical tools, is moving to defend its bariatric surgery territory as a slew of noninvasive medical devices to treat obesity line up to gain approval in the U.S. It will spend $3.2 million on more than 20 clinical trials to examine how early surgical intervention can be used to improve conditions such as obesity and Type 2 diabetes.

GSK doubles down on Singapore continuous processing plant

Several years ago, GlaxoSmithKline committed $50 million to set up an antibiotics facility in Singapore to do continuous processing, a radically different manufacturing approach that has a much smaller footprint, and so much lower operating costs and less environmental impact, than traditional batch processing. The drugmaker now says it is ready to embark on a £38 million expansion there.

Broad Institute gets $20M to target TB from Wall Street-led philanthropists

Hedge fund managers are so flush that now they're giving money away. A pair of prominent fund heads have led a collection of wealthy individuals to back a project at the Broad Institute of MIT and Harvard researching the bacteria behind tuberculosis with $20 million. The goal is to better understand the bacteria itself, as well as how drug resistance forms in it and to develop a rapid diagnostic test for drug-resistant TB.

Chinese med tech gets the WHO's OK for circumcision device

China is a hotbed of med tech growth, with local companies competing against foreign devicemakers for their cut of the profits. One Chinese company got a boost in the race, as the World Health Organization (WHO) approved Wuhu SNNDA Medical Treatment Appliance Technology's circumcision device for HIV prevention.

Valeant said to step up talks on potential $800M deal for Egypt's Amoun

Last month, reports said Valeant was eyeing up one of Egypt's largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.

Move over, India--China can make WHO-approved vaccines, too

China's growing vaccine industry scored again on Friday when the World Health Organization announced that it had approved a Chinese flu vaccine.

Pfizer supplements its China production with $90M plant

Pfizer has broken ground on a $90 million facility that is being built in Suzhou, China, it announced Monday. The additional capacity is needed as demand for its supplements grows in the Asia-Pacific region, particularly in China.

MSF wants Indian PM to stand up to Big Pharma peer pressure

Western drugmakers have long struggled with India's populist attitude toward patents, but hoped there would be some light at the end of the tunnel with the latest spate of trade negotiations over generic drugs in the country. But Doctors Without Borders is none too pleased with the proposed trade changes and is urging Prime Minister Narendra Modi to adopt a similar attitude and stand up to international pressure.

Second investigator linked to GSK bribery scandal released from Chinese prison

Earlier this week, Chinese authorities released Peter Humphrey--a private eye linked to GlaxoSmithKline's 2013 bribery scandal--from local prison after a court reduced his sentence by about 7 months. And now,  The Wall Street Journal  reports that they've released his wife and partner Yu Yingzeng, too, cutting short her sentence by one month.